Abiomed receives Impella Class III blow, but might escape cost of new trial
This article was originally published in Clinica
Executive Summary
An FDA advisory panel has recommended Class III designation for Abiomed's Impella 2.5 heart pump, as predicted. However, even though the device looks likely to now be regulated under premarket approval (PMA) rather than 510(k) regulations, the company may have got off relatively lightly: it may not necessarily need to conduct a new clinical trial, according to Morgan Stanley analyst David Lewis.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.